The psychometric properties of the Collaborative Assessment and Management of Suicidality rating scale

Corona, Christopher D.; Gutierrez, Peter M.; Wagner, Barry M.; Jobes, David A.

doi:10.1002/jclp.22699

Cited by 9 publications

(6 citation statements)

References 33 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, oral PREG as antipsychotic monotherapy or as anti-inflammatory adjuvant therapy improved cognitive function and reduced negative symptoms (anxiety, depression) in patients with schizophrenia and bipolar disorder (Brown et al, 2014;Cho et al, 2019;Kreinin, Bawakny, & Ritsner, 2017;Marx et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Intranasal pregnenolone increases acetylcholine in frontal cortex, hippocampus, and amygdala—Preferentially in the hemisphere ipsilateral to the injected nostril

Fazari

Decheva

García

et al. 2019

Journal of Neurochemistry

View full text Add to dashboard Cite

This study determined the effects of intranasal pregnenolone (IN-PREG) on acetylcholine (ACh) levels in selected areas of the rat brain, using in vivo microdialysis.Previous studies showed that PREG rapidly reaches the rodent brain after intranasal administration and that direct infusion of PREG and PREG-S into the basal forebrain modulates ACh release in frontal cortex, amygdala, and hippocampus. In the present study, we investigated the effects of IN-PREG on the cholinergic system in the rat brain. In the first experiment, IN-PREG (5.6 and 11.2 mg/ml) or vehicle was applied bilaterally, and we hypothesized that IN-PREG would increase ACh levels in amygdala, hippocampus, and frontal cortex, relative to baseline and vehicle. Dialysate was collected for 100 min, based on pilot data of duration of effect. Bilateral IN-PREG (5.6 and 11.2 mg/ml) increased frontal cortex and hippocampal ACh relative to both baseline and vehicle. Moreover, 11.2 mg/ml PREG increased ACh in the amygdala relative to baseline, the lower dose, and vehicle. Therefore, in the second experiment, IN-PREG (11.2 mg/ml) was applied only into one nostril, with vehicle applied into the other nostril, in order to determine whether ACh is predominantly increased in the ipsilateral relative to the contralateral amygdala. Unilateral application of IN-PREG increased ACh in the ipsilateral amygdala, whereas no effect was observed on the contralateral side, suggesting that PREG was transported from the nostrils to the brain via the olfactory epithelial pathway, but not by circulation. The present data provide additional information on IN-PREG action in the cholinergic system of frontal cortex, amygdala, and hippocampus. This may be relevant for therapeutic IN application of PREG in neurogenerative and neuropsychiatric disorders. K E Y W O R D Sacetylcholine, intranasal pregnenolone, microdialysis, rat

show abstract

Section: Discussionmentioning

confidence: 99%

Intranasal pregnenolone increases acetylcholine in frontal cortex, hippocampus, and amygdala—Preferentially in the hemisphere ipsilateral to the injected nostril

Fazari

Decheva

García

et al. 2019

Journal of Neurochemistry

View full text Add to dashboard Cite

show abstract

“…CAMS clinicians received a 1.5‐day training from DAJ and participated in weekly group consultation calls. Review of video recordings of initial CAMS sessions with all patients and random checks with 10% of patients were used to confirm between‐group fidelity, treatment adherence, and absence of drift (Corona, Gutierrez, Wagner, & Jobes, ).…”

Section: Methodsmentioning

confidence: 99%

A Preliminary Precision Treatment Rule for Remission of Suicide Ideation

Kessler

Chalker

Luedtke

et al. 2019

Suicide & Life Threat Behav

Self Cite

View full text Add to dashboard Cite

Objective There is growing interest in the development of composite precision treatment rules (PTRs) to guide the selection of the treatments most likely to be helpful for individual patients. We present here the results of an effort to develop a preliminary PTR for Collaborative Assessment and Management of Suicidality (CAMS) relative to enhanced‐care as usual based on secondary analysis of the Operation Worth Living (OWL) randomized controlled trial. The outcome of interest is eliminating suicide ideation (SI) within 3 months of initiating treatment. Method A state‐of‐the‐art ensemble machine learning method was used to develop the PTR among the n = 148 U.S. Soldiers (predominately male and White, age range 18–48) OWL patients. Results We estimated that CAMS was the better treatment for 77.8% of patients and that treatment assignment according to the PTR would result in a 13.6% (95% CI: 0.9%–26.3%) increase in 3‐month SI remission compared to random treatment assignment. Conclusions Although promising, results are limited by the small sample size, restrictive baseline assessment, and inability to evaluate effects on suicidal behaviors or disaggregate based on history of suicidal behaviors. Replication is needed in larger samples with comprehensive baseline assessments, longer‐term follow‐ups, and more extensive outcomes.

show abstract

“…Each therapy session was audiotaped. Every fourth treatment session of the therapists in both treatment conditions was supervised and rated for adherence according to the CAMS Rating Scale (CRS) (71,72) by external evaluators. The CRS is an observer rating scale and consists of three parts and 14 items in total.…”

Section: Therapistsmentioning

confidence: 99%

The Collaborative Assessment and Management of Suicidality compared to enhanced treatment as usual for inpatients who are suicidal: A randomized controlled trial

Santel

Neuner²,

Berg³

et al. 2023

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough use of inpatient crisis hospital intervention for suicide risk is common, the evidence for inpatient treatments that reduce suicidal thoughts and behaviors is remarkably limited. To address this need, this novel feasibility pilot randomized controlled trial compared the use of the Collaborative Assessment and Management of Suicidality (CAMS) to enhanced treatment as usual (E-TAU) within a standard acute inpatient mental health care setting.ObjectivesWe hypothesized that CAMS would be more effective than E-TAU in reducing suicidal thoughts and behaviors. As secondary outcomes we also investigated depressive symptoms, general symptom burden, reasons for living, and quality of the therapeutic relationship.MethodsAll patients were admitted due to acute suicidal thoughts or behaviors. They were randomly assigned to CAMS (n = 43) or E-TAU (n = 45) and assessed at four time points (admission, discharge, 1 month and 5 months after discharge). We used mixed-effects models, effect sizes, and reliable change analyses to compare improvements across and between treatment groups over time.ResultsIntent-to-treat analyses of 88 participants [mean age 32.1, SD = 13.5; n = 47 (53%) females] showed that both groups improved over time across all outcome measures with no significant between-group differences in terms of change in suicidal ideation, depression, reasons for living, and distress. However, CAMS showed larger effect sizes across all measures; for treatment completers CAMS patients showed significant improvement in suicidal ideation (p = 0.01) in comparison to control patients. CAMS patients rated the therapeutic relationship significantly better (p = 0.02) than E-TAU patients and were less likely to attempt suicide within 4 weeks after discharge (p = 0.05).ConclusionsCAMS and E-TAU were both effective in reducing suicidal thoughts and symptom distress. Within this feasibility RCT the pattern of results was generally supportive of CAMS suggesting that inpatient use of CAMS is both feasible and promising. However, our preliminary results need further replication within well-powered multi-site randomized controlled trials.Trial registrationDRKS-ID/ICTRP-ID: DRKS00013727. The trial was retrospectively registered in the German Clinical Trials Register, registration code/ DRKS-ID: DRKS00013727 on 12.01.2018 and also in the International Clinical Trials Registry Platform of the World Health Organization (identical registration code).

show abstract

The psychometric properties of the Collaborative Assessment and Management of Suicidality rating scale

Cited by 9 publications

References 33 publications

Intranasal pregnenolone increases acetylcholine in frontal cortex, hippocampus, and amygdala—Preferentially in the hemisphere ipsilateral to the injected nostril

Intranasal pregnenolone increases acetylcholine in frontal cortex, hippocampus, and amygdala—Preferentially in the hemisphere ipsilateral to the injected nostril

A Preliminary Precision Treatment Rule for Remission of Suicide Ideation

The Collaborative Assessment and Management of Suicidality compared to enhanced treatment as usual for inpatients who are suicidal: A randomized controlled trial

Contact Info

Product

Resources

About